Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free IDYA Stock Alerts

IDEAYA Biosciences (IDYA) Financials

IDEAYA Biosciences logo
$28.84 -0.06 (-0.21%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$29.25 +0.41 (+1.42%)
As of 05/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for IDEAYA Biosciences

Annual Income Statements for IDEAYA Biosciences

This table shows IDEAYA Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -34 -42 -35 -50 -59 -113 -274 -114
Consolidated Net Income / (Loss)		 -34 -42 -34 -50 -59 -113 -274 -114
Net Income / (Loss) Continuing Operations		 -34 -42 -34 -50 -59 -113 -274 -114
Total Pre-Tax Income 		-36 -44 -35 -50 -63 -113 -274 -114
Total Operating Income		 -36 -44 -35 -50 -63 -134 -327 -159
Total Gross Profit		 0.00 0.00 20 28 51 23 7.00 219
Total Revenue		 0.00 0.00 20 28 51 23 7.00 219
Operating Revenue		 0.00 0.00 20 28 51 23 7.00 219
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 36 44 55 78 113 158 334 378
Selling, General & Admin Expense		 4.67 9.95 15 20 24 28 39 63
Research & Development Expense		 32 34 40 58 90 130 295 315
Total Other Income / (Expense), net		 0.00 0.00 0.00 0.51 0.00 21 52 46
Other Income / (Expense), net		 - - - 0.51 - 21 52 46
Basic Earnings per Share		 ($35.92) ($3.36) ($1.40) ($1.41) ($1.42) ($1.96) ($3.36) ($1.28)
Weighted Average Basic Shares Outstanding		 956.25K 12.50M 24.72M 35.25M 41.44M 57.52M 81.68M 88.49M
Diluted Earnings per Share		 ($35.92) ($3.36) ($1.40) ($1.41) ($1.42) ($1.96) ($3.36) ($1.28)
Weighted Average Diluted Shares Outstanding		 956.25K 12.50M 24.72M 35.25M 41.44M 57.52M 81.68M 88.49M
Weighted Average Basic & Diluted Shares Outstanding		 956.25K 12.50M 24.72M 35.25M 48.39M 74.56M 87.54M 87.81M

Quarterly Income Statements for IDEAYA Biosciences

This table shows IDEAYA Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -27 -35 -40 -53 -52 -135 -72 -77 119 -83 -99
Consolidated Net Income / (Loss)		 -27 -34 -40 -53 -52 -130 -72 -77 119 -83 -99
Net Income / (Loss) Continuing Operations		 -27 -34 -40 -53 -52 -130 -72 -77 119 -83 -99
Total Pre-Tax Income 		-34 -45 -51 -65 -67 -156 -72 -89 108 -61 -99
Total Operating Income		 -34 -42 -51 -65 -67 -144 -84 -89 108 -95 -109
Total Gross Profit		 8.04 3.92 0.00 0.00 0.00 7.00 0.00 0.00 208 11 6.56
Total Revenue		 8.04 3.92 0.00 0.00 0.00 7.00 0.00 0.00 208 11 6.56
Operating Revenue		 8.04 3.92 0.00 0.00 0.00 7.00 0.00 0.00 208 11 6.56
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 42 46 51 65 67 151 84 89 99 105 115
Selling, General & Admin Expense		 7.86 7.07 8.21 10 9.74 11 14 15 16 19 19
Research & Development Expense		 34 39 43 55 57 140 71 74 83 87 96
Total Other Income / (Expense), net		 0.00 -2.64 0.00 0.00 0.00 -11 12 0.00 0.00 33 10
Other Income / (Expense), net		 - - - - - - 12 - - - 10
Basic Earnings per Share		 ($0.46) ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82) ($0.88) $1.35 ($0.93) ($1.11)
Weighted Average Basic Shares Outstanding		 60.00M 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M 88.47M 88.53M 88.49M 88.70M
Diluted Earnings per Share		 ($0.46) ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82) ($0.88) $1.33 ($0.91) ($1.11)
Weighted Average Diluted Shares Outstanding		 60.00M 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M 88.47M 89.69M 88.49M 88.70M
Weighted Average Basic & Diluted Shares Outstanding		 64.46M 74.56M 75.69M 84.48M 86.43M 87.54M 87.58M 87.64M 87.67M 87.81M 87.86M

Annual Cash Flow Statements for IDEAYA Biosciences

This table details how cash moves in and out of IDEAYA Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 15 14 38 20 -23 89 -73 29
Net Cash From Operating Activities		 -28 -39 55 -56 -87 -115 -248 -71
Net Cash From Continuing Operating Activities		 -28 -39 55 -56 -87 -115 -248 -71
Net Income / (Loss) Continuing Operations		 -34 -42 -34 -50 -59 -113 -274 -114
Consolidated Net Income / (Loss)		 -34 -42 -34 -50 -59 -113 -274 -114
Depreciation Expense		 0.89 1.25 1.38 1.73 2.10 2.48 2.39 2.70
Amortization Expense		 -0.81 -0.47 0.58 3.14 0.72 -10 -22 -8.08
Non-Cash Adjustments To Reconcile Net Income		 4.99 3.27 3.59 -15 -35 18 35 46
Changes in Operating Assets and Liabilities, net		 1.65 -1.38 84 4.42 3.51 -13 12 1.87
Net Cash From Investing Activities		 -63 2.27 -146 -70 -33 -158 -503 70
Net Cash From Continuing Investing Activities		 -63 2.27 -146 -70 -33 -158 -503 70
Purchase of Property, Plant & Equipment		 -1.71 -1.35 -0.49 -2.64 -3.44 -2.37 -3.86 -2.37
Purchase of Investments		 -133 -88 -242 -315 -256 -596 -1,191 -608
Sale and/or Maturity of Investments		 72 92 97 248 226 440 693 680
Net Cash From Financing Activities		 105 51 129 145 97 363 678 30
Net Cash From Continuing Financing Activities		 105 51 129 145 97 363 678 30
Issuance of Common Equity		 0.00 50 128 144 96 353 665 26
Other Financing Activities, net		 0.09 0.29 1.19 1.50 1.45 9.56 12 3.43
Cash Interest Paid		 0.10 0.09 0.08 0.07 0.06 0.07 0.03 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for IDEAYA Biosciences

This table details how cash moves in and out of IDEAYA Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 49 5.20 -49 75 217 -316 46 -15 184 -186 45
Net Cash From Operating Activities		 -30 -24 -44 -33 -49 -122 -60 -62 142 -90 -75
Net Cash From Continuing Operating Activities		 -30 -24 -44 -33 -49 -122 -60 -62 142 -90 -75
Net Income / (Loss) Continuing Operations		 -27 -34 -40 -53 -52 -130 -72 -77 119 -83 -99
Consolidated Net Income / (Loss)		 -27 -34 -40 -53 -52 -130 -72 -77 119 -83 -99
Depreciation Expense		 0.64 0.63 0.62 0.62 0.58 0.57 0.60 0.72 0.66 0.72 0.69
Amortization Expense		 -3.18 -3.48 -5.85 -6.17 -4.93 -4.85 -3.25 -2.18 -1.61 -1.05 -0.76
Non-Cash Adjustments To Reconcile Net Income		 5.30 -8.96 6.31 9.73 9.22 9.49 10 12 12 12 15
Changes in Operating Assets and Liabilities, net		 -5.50 22 -5.32 16 -2.28 3.45 4.24 4.61 12 -19 8.90
Net Cash From Investing Activities		 51 -112 -354 69 -20 -197 80 46 42 -98 119
Net Cash From Continuing Investing Activities		 51 -112 -354 69 -20 -197 80 46 42 -98 119
Purchase of Property, Plant & Equipment		 -0.60 -0.84 -1.33 -0.97 -0.46 -1.10 -1.33 -0.66 -0.04 -0.33 -0.97
Purchase of Investments		 -82 -222 -476 -165 -214 -337 -105 -128 -139 -236 -43
Sale and/or Maturity of Investments		 134 111 123 234 194 141 186 174 181 139 163
Net Cash From Financing Activities		 28 141 349 39 287 2.75 26 1.21 0.30 2.13 1.18
Net Cash From Continuing Financing Activities		 28 141 349 39 287 2.75 26 1.21 0.30 2.13 1.19
Issuance of Common Equity		 26 135 344 37 284 0.25 25 0.80 -0.08 0.63 0.00
Other Financing Activities, net		 1.86 5.85 5.46 2.08 2.44 2.50 1.13 0.41 0.38 1.50 1.19
Cash Interest Paid		 0.01 0.03 0.01 0.01 0.00 - 0.00 - - - 0.00

Annual Balance Sheets for IDEAYA Biosciences

This table presents IDEAYA Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 97 113 298 381 388 649 1,124 1,109
Total Current Assets		 91 102 289 251 370 533 690 667
Cash & Equivalents		 21 34 72 92 69 157 84 113
Short-Term Investments		 69 65 212 155 296 368 592 527
Accounts Receivable		 - 0.00 1.88 1.10 0.21 0.02 0.00 0.00
Prepaid Expenses		 0.71 2.70 3.14 3.12 5.41 7.50 13 21
Other Current Assets		 - - - - - - 0.00 5.97
Plant, Property, & Equipment, net		 5.15 4.64 4.27 4.76 6.51 6.16 8.97 8.22
Total Noncurrent Assets		 0.72 6.71 5.39 126 11 111 425 434
Long-Term Investments		 - 1.53 0.00 121 8.32 107 406 410
Other Noncurrent Operating Assets		 0.72 5.18 5.39 4.30 2.69 3.03 20 24
Total Liabilities & Shareholders' Equity		 97 113 298 381 388 649 1,124 1,109
Total Liabilities		 7.10 13 100 80 39 28 65 86
Total Current Liabilities		 5.41 6.94 39 45 32 27 46 59
Accounts Payable		 1.42 0.71 0.95 2.10 4.28 6.60 15 18
Accrued Expenses		 3.58 5.02 8.52 12 17 19 30 41
Current Deferred Revenue		 0.30 0.00 28 29 8.57 0.00 0.00 0.00
Other Current Liabilities		 0.11 1.21 1.56 1.70 1.87 1.75 0.30 0.34
Total Noncurrent Liabilities		 1.69 5.66 61 35 6.80 1.13 19 28
Noncurrent Deferred Revenue		 1.57 0.00 56 31 5.19 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.11 5.66 5.20 3.48 1.61 1.13 19 28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -49 100 198 302 349 621 1,059 1,023
Total Preferred & Common Equity		 -49 100 198 302 349 621 1,059 1,023
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -49 100 198 302 349 621 1,059 1,023
Common Stock		 1.60 193 325 479 588 969 1,681 1,757
Retained Earnings		 -51 -92 -127 -177 -235 -348 -623 -737
Accumulated Other Comprehensive Income / (Loss)		 -0.03 0.07 0.01 -0.71 -2.87 0.56 0.81 2.27

Quarterly Balance Sheets for IDEAYA Biosciences

This table presents IDEAYA Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 411 365 528 533 962 974 1,240 1,101 1,041 1,185 1,030
Total Current Assets		 393 344 502 482 709 713 932 708 686 803 696
Cash & Equivalents		 102 67 103 152 108 183 400 130 115 299 158
Short-Term Investments		 284 272 391 317 590 519 520 563 555 488 514
Accounts Receivable		 3.45 0.47 0.16 6.70 0.02 0.00 0.02 0.00 0.00 0.00 0.00
Prepaid Expenses		 3.74 4.02 7.91 6.73 11 12 12 15 16 16 18
Other Current Assets		 - - - - - - - - - - 6.56
Plant, Property, & Equipment, net		 6.68 6.72 6.83 6.19 6.91 7.12 8.24 8.87 8.82 8.17 8.63
Total Noncurrent Assets		 11 14 19 45 245 253 299 384 347 374 326
Long-Term Investments		 7.69 12 16 42 243 251 280 359 322 350 302
Other Noncurrent Operating Assets		 3.10 2.33 2.56 2.17 2.63 2.29 19 25 25 24 24
Total Liabilities & Shareholders' Equity		 411 365 528 533 962 974 1,240 1,101 1,041 1,185 1,030
Total Liabilities		 42 31 26 25 26 42 59 77 82 93 93
Total Current Liabilities		 33 30 25 25 25 41 41 51 55 65 65
Accounts Payable		 3.65 4.38 5.87 5.17 6.29 16 13 18 17 18 21
Accrued Expenses		 17 17 15 16 18 24 28 33 38 45 44
Current Deferred Revenue		 10 6.26 2.82 1.44 0.00 - - - - 0.49 0.00
Other Current Liabilities		 1.83 1.92 1.96 2.10 1.15 0.61 0.00 0.31 0.32 0.33 0.35
Total Noncurrent Liabilities		 9.41 1.12 0.61 0.00 1.26 1.26 19 26 26 29 28
Noncurrent Deferred Revenue		 7.31 0.00 0.00 0.00 0.00 - - - - 1.68 0.00
Other Noncurrent Operating Liabilities		 2.10 1.12 0.61 0.00 1.26 1.26 19 26 26 27 28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 369 334 502 508 935 932 1,180 1,024 960 1,092 937
Total Preferred & Common Equity		 369 334 502 508 935 932 1,180 1,024 960 1,092 937
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 369 334 502 508 935 932 1,180 1,024 960 1,092 937
Common Stock		 584 594 790 823 1,324 1,374 1,669 1,718 1,731 1,743 1,773
Retained Earnings		 -211 -259 -287 -314 -388 -441 -493 -695 -773 -653 -835
Accumulated Other Comprehensive Income / (Loss)		 -4.00 -1.41 -1.18 -0.75 -0.92 -1.42 3.84 1.59 1.52 2.05 -0.49

Annual Metrics And Ratios for IDEAYA Biosciences

This table displays calculated financial ratios and metrics derived from IDEAYA Biosciences' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 43.01% 82.28% -54.08% -70.07% 3,024.43%
EBITDA Growth		 0.00% -19.70% 23.25% -34.48% -32.93% -137.88% -143.97% 59.48%
EBIT Growth		 0.00% -21.57% 20.16% -40.79% -25.60% -115.08% -143.23% 58.58%
NOPAT Growth		 0.00% -21.57% 20.16% -42.23% -24.34% -115.08% -143.23% 51.28%
Net Income Growth		 0.00% -22.21% 17.82% -44.26% -17.87% -92.59% -142.98% 58.58%
EPS Growth		 0.00% 90.65% 58.33% -0.71% -0.71% -38.03% -71.43% 61.90%
Operating Cash Flow Growth		 0.00% -42.34% 241.08% -200.57% -56.29% -32.18% -114.87% 71.28%
Free Cash Flow Firm Growth		 0.00% 0.00% 292.48% -189.19% -60.54% -22.71% -104.56% 50.43%
Invested Capital Growth		 0.00% 84.17% -103,937.80% 21.99% 64.40% 51.39% -99.76% -16.29%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -21.40% 2.13% -0.42% 78.43% 1.80%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -36.93% -19.01% -14.63% -42.70% 45.43%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -33.84% -14.83% -13.01% -45.48% 45.57%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -35.21% -14.83% -13.01% -45.48% 23.73%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -35.65% -11.37% -9.45% -54.10% 29.26%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -45.36% -2.90% 1.01% -44.83% 33.33%
Operating Cash Flow Q/Q Growth		 0.00% -3.23% -4.95% -9.98% -8.34% -0.33% -65.41% 30.47%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -6.83% -0.89% -54.53% 11.03%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 2.33% 5.86% -271.96% -16.54% 40.31%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -170.87% -160.68% -117.18% -607.12% -4,948.20% -54.45%
Operating Margin		 0.00% 0.00% -180.90% -179.91% -122.72% -574.85% -4,671.07% -72.84%
EBIT Margin		 0.00% 0.00% -180.90% -178.10% -122.72% -574.85% -4,671.07% -51.99%
Profit (Net Income) Margin		 0.00% 0.00% -176.55% -178.10% -115.17% -483.05% -3,921.10% -51.99%
Tax Burden Percent		 94.31% 94.81% 97.60% 100.00% 93.85% 84.03% 83.94% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -38.40% -44.22% -23.10% -19.91% -18.02% -23.28% -32.67% -10.92%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -17.19% -14.64% -16.25% -25.92% -36.88% -10.18%
Return on Assets (ROA)		 0.00% 0.00% -16.77% -14.64% -15.25% -21.78% -30.95% -10.18%
Return on Common Equity (ROCE)		 21.01% -11.98% -23.10% -19.91% -18.02% -23.28% -32.67% -10.92%
Return on Equity Simple (ROE_SIMPLE)		 70.17% -41.81% -17.40% -16.50% -16.78% -18.19% -25.91% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -31 -25 -35 -44 -94 -229 -112
NOPAT Margin		 0.00% 0.00% -126.63% -125.94% -85.90% -402.40% -3,269.75% -50.99%
Net Nonoperating Expense Percent (NNEP)		 -9.84% -11.54% -5.08% -4.47% -4.02% -3.75% -5.32% -0.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -12.52% -15.15% -21.61% -10.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 77.72% 71.76% 46.92% 121.04% 561.46% 28.95%
R&D to Revenue		 0.00% 0.00% 203.18% 208.15% 175.80% 553.81% 4,209.61% 143.89%
Operating Expenses to Revenue		 0.00% 0.00% 280.90% 279.91% 222.72% 674.85% 4,771.07% 172.84%
Earnings before Interest and Taxes (EBIT)		 -36 -44 -35 -50 -63 -134 -327 -114
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -43 -33 -45 -60 -142 -346 -119
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 1.52 2.05 3.02 2.50 3.69 2.10 2.96
Price to Tangible Book Value (P/TBV)		 0.00 1.52 2.05 3.02 2.50 3.69 2.10 2.96
Price to Revenue (P/Rev)		 0.00 0.00 20.83 32.57 17.16 98.07 317.33 13.86
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 6.32 19.40 9.84 71.02 162.74 9.06
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 2.22 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 2.04 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.00 -1.29 -1.30 -1.14 -1.04 -1.02 -1.02
Leverage Ratio		 1.08 1.10 1.38 1.36 1.18 1.07 1.06 1.07
Compound Leverage Factor		 1.08 1.10 1.38 1.36 1.18 1.07 1.06 1.07
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 154.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -54.73% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.31 5.83 2.53 6.48 13.42 48.29 19.48 20.64
Noncontrolling Interest Sharing Ratio		 154.73% 72.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 16.75 14.65 7.47 5.56 11.68 19.65 14.97 11.34
Quick Ratio		 16.62 14.26 7.39 5.49 11.51 19.38 14.68 10.87
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -31 60 -54 -87 -106 -217 -108
Operating Cash Flow to CapEx		 -1,617.10% -2,905.62% 11,250.10% -2,109.64% -2,531.95% -4,865.88% -6,419.08% -3,002.45%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.10 0.08 0.13 0.05 0.01 0.20
Accounts Receivable Turnover		 0.00 0.00 0.00 18.75 77.52 204.24 666.67 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 4.38 6.19 9.04 3.69 0.93 25.46
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 19.46 4.71 1.79 0.55 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 19.46 4.71 1.79 0.55 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -0.52 -0.08 -85 -67 -24 -12 -23 -27
Invested Capital Turnover		 0.00 0.00 -0.46 -0.37 -1.13 -1.33 -0.41 -8.79
Increase / (Decrease) in Invested Capital		 0.00 0.44 -85 19 43 12 -11 -3.75
Enterprise Value (EV)		 98 52 123 542 501 1,661 1,139 1,981
Market Capitalization		 50 152 407 910 874 2,293 2,221 3,031
Book Value per Share		 ($51.19) $4.94 $6.82 $7.83 $7.26 $9.64 $12.25 $11.67
Tangible Book Value per Share		 ($51.19) $4.94 $6.82 $7.83 $7.26 $9.64 $12.25 $11.67
Total Capital		 89 100 198 302 349 621 1,059 1,023
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -90 -100 -284 -368 -373 -633 -1,082 -1,050
Capital Expenditures (CapEx)		 1.71 1.35 0.49 2.64 3.44 2.37 3.86 2.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.71 -4.24 -34 -41 -26 -20 -33 -31
Debt-free Net Working Capital (DFNWC)		 85 95 250 206 339 506 644 608
Net Working Capital (NWC)		 85 95 250 206 339 506 644 608
Net Nonoperating Expense (NNE)		 8.85 11 9.75 15 15 19 46 2.18
Net Nonoperating Obligations (NNO)		 -90 -100 -284 -368 -373 -633 -1,082 -1,050
Total Depreciation and Amortization (D&A)		 0.08 0.77 1.96 4.87 2.82 -7.55 -19 -5.38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -172.07% -146.50% -51.23% -83.74% -466.81% -14.39%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,279.38% 736.68% 665.09% 2,161.77% 9,194.89% 277.95%
Net Working Capital to Revenue		 0.00% 0.00% 1,279.38% 736.68% 665.09% 2,161.77% 9,194.89% 277.95%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.40) ($1.41) ($1.42) ($1.96) ($3.36) ($1.28)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 32.26M 38.63M 41.44M 57.52M 81.68M 88.49M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.40) ($1.41) ($1.42) ($1.96) ($3.36) ($1.28)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 32.26M 38.63M 41.44M 57.52M 81.68M 88.49M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.40) ($1.41) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 24.72M 35.25M 48.39M 74.56M 87.54M 87.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -31 -25 -35 -44 -94 -229 -112
Normalized NOPAT Margin		 0.00% 0.00% -126.63% -125.94% -85.90% -402.40% -3,269.75% -50.99%
Pre Tax Income Margin		 0.00% 0.00% -180.90% -178.10% -122.72% -574.85% -4,671.07% -51.99%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for IDEAYA Biosciences

This table displays calculated financial ratios and metrics derived from IDEAYA Biosciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 87,814,027.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 87,814,027.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.12
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -72.94% -2.46% -100.00% -100.00% -100.00% 78.43% 0.00% 0.00% 0.00% 55.37% 0.00%
EBITDA Growth		 -2,506.00% -67.99% -84.86% -105.66% -97.54% -231.52% -33.02% -28.09% 250.89% 36.06% -31.79%
EBIT Growth		 -5,179.70% -58.51% -67.39% -98.50% -99.53% -243.88% -41.48% -36.78% 262.13% 34.39% -36.52%
NOPAT Growth		 -3,655.79% -58.51% -94.14% -98.50% -99.53% -243.88% -65.41% -36.78% 331.61% 34.39% -28.62%
Net Income Growth		 -1,799.07% -40.30% -67.39% -88.97% -88.85% -283.78% -82.40% -46.84% 330.11% 36.10% -36.52%
EPS Growth		 -1,250.00% 3.77% -8.16% -36.00% -30.43% -203.92% -54.72% -29.41% 321.67% 41.29% -35.37%
Operating Cash Flow Growth		 -24.86% -1.62% -57.36% 1.73% -63.17% -412.27% -37.73% -89.99% 388.85% 25.61% -24.57%
Free Cash Flow Firm Growth		 -7.62% 32.35% 19.71% 52.29% 33.72% -115.36% 18.90% -55.25% 542.42% 30.15% -76.68%
Invested Capital Growth		 87.70% 51.39% 64.96% -148.36% -537.56% -99.76% -343.46% -52.89% -127.06% -16.29% -31.84%
Revenue Q/Q Growth		 126.81% -51.19% -100.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% -94.77% -39.68%
EBITDA Q/Q Growth		 -5.26% -24.13% -0.08% -57.29% -1.10% -108.31% 49.58% -20.64% 219.09% -188.28% -3.91%
EBIT Q/Q Growth		 -2.50% -25.02% 5.59% -64.07% -3.03% -115.48% 49.92% -23.04% 222.12% -187.20% -4.20%
NOPAT Q/Q Growth		 -2.50% -25.02% -21.72% -27.27% -3.03% -115.48% 41.45% -5.23% 274.46% -161.04% -14.78%
Net Income Q/Q Growth		 1.74% -23.74% -16.54% -33.36% 1.80% -151.47% 44.61% -7.36% 253.88% -169.83% -18.33%
EPS Q/Q Growth		 8.00% -10.87% -3.92% -28.30% 11.76% -158.33% 47.10% -7.32% 251.14% -168.42% -21.98%
Operating Cash Flow Q/Q Growth		 9.82% 21.30% -84.49% 24.95% -49.73% -147.10% 50.40% -3.53% 327.64% -163.63% 16.94%
Free Cash Flow Firm Q/Q Growth		 33.89% 8.83% -13.25% 30.10% 8.15% -196.23% 57.35% -33.80% 361.73% -146.77% -7.88%
Invested Capital Q/Q Growth		 63.51% -271.96% 47.06% -245.60% 6.32% -16.54% -17.54% -19.15% -39.12% 40.31% -33.25%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -448.69% -1,141.14% 0.00% 0.00% 0.00% -2,120.16% 0.00% 0.00% 51.72% -872.54% -1,503.16%
Operating Margin		 -417.09% -1,068.44% 0.00% 0.00% 0.00% -2,059.11% 0.00% 0.00% 52.18% -869.53% -1,654.63%
EBIT Margin		 -417.09% -1,068.44% 0.00% 0.00% 0.00% -2,059.11% 0.00% 0.00% 52.18% -869.53% -1,502.12%
Profit (Net Income) Margin		 -341.38% -865.54% 0.00% 0.00% 0.00% -1,861.60% 0.00% 0.00% 57.37% -765.66% -1,502.12%
Tax Burden Percent		 81.85% 76.21% 100.00% 81.28% 77.47% 83.76% 100.00% 87.26% 109.95% 136.14% 100.00%
Interest Burden Percent		 100.00% 106.30% 100.00% 100.00% 100.00% 107.94% 100.00% 100.00% 100.00% 64.68% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -23.54% -23.28% -20.31% -21.45% -21.10% -32.67% -31.34% -35.09% -14.15% -10.92% -14.28%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -20.76% -48.17% 0.00% 0.00% 0.00% -16.26% 0.00% 0.00% 9.25% -170.30% -317.58%
Return on Assets (ROA)		 -16.99% -39.03% 0.00% 0.00% 0.00% -14.70% 0.00% 0.00% 10.17% -149.96% -317.58%
Return on Common Equity (ROCE)		 -23.54% -23.28% -20.31% -21.45% -21.10% -32.67% -31.34% -35.09% -14.15% -10.92% -14.28%
Return on Equity Simple (ROE_SIMPLE)		 -20.31% 0.00% -13.78% -16.50% -15.09% 0.00% -29.98% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -23 -29 -36 -45 -47 -101 -59 -62 108 -66 -76
NOPAT Margin		 -291.97% -747.91% 0.00% 0.00% 0.00% -1,441.38% 0.00% 0.00% 52.18% -608.67% -1,158.24%
Net Nonoperating Expense Percent (NNEP)		 -0.88% -0.92% -0.60% -1.00% -0.58% -3.43% -1.32% -1.58% 0.92% -1.60% -2.23%
Return On Investment Capital (ROIC_SIMPLE)		 - -4.72% - - - -9.53% -5.77% -6.48% 9.93% -6.47% -8.11%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 97.82% 180.17% 0.00% 0.00% 0.00% 156.50% 0.00% 0.00% 7.89% 173.29% 295.40%
R&D to Revenue		 419.27% 988.27% 0.00% 0.00% 0.00% 2,002.61% 0.00% 0.00% 39.93% 796.24% 1,459.24%
Operating Expenses to Revenue		 517.09% 1,168.44% 0.00% 0.00% 0.00% 2,159.11% 0.00% 0.00% 47.82% 969.53% 1,754.63%
Earnings before Interest and Taxes (EBIT)		 -34 -42 -40 -65 -67 -144 -72 -89 108 -95 -99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -45 -45 -70 -71 -148 -75 -90 108 -95 -99
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.06 3.69 3.02 2.85 2.27 2.10 1.40 1.92 2.18 2.96 3.12
Price to Tangible Book Value (P/TBV)		 3.06 3.69 3.02 2.85 2.27 2.10 1.40 1.92 2.18 2.96 3.12
Price to Revenue (P/Rev)		 66.13 98.07 182.42 222.17 682.23 317.33 204.84 263.00 11.10 13.86 12.99
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 44.36 71.02 121.71 142.52 376.30 162.74 54.67 121.30 5.81 9.06 8.67
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.04 -1.02 -1.02 -1.01 -1.02 -1.02 -1.03 -1.03 -1.02 -1.03
Leverage Ratio		 1.08 1.07 1.05 1.05 1.05 1.06 1.05 1.07 1.07 1.07 1.09
Compound Leverage Factor		 1.08 1.14 1.05 1.05 1.05 1.14 1.05 1.07 1.07 0.69 1.09
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 37.47 48.76 64.90 37.95 27.14 20.02 10.87 12.95 15.83 20.69 18.36
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 19.37 19.65 28.42 17.50 22.93 14.97 13.92 12.39 12.44 11.34 10.74
Quick Ratio		 19.10 19.38 28.00 17.22 22.63 14.68 13.62 12.10 12.20 10.87 10.35
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -46 -42 -47 -33 -30 -89 -38 -51 134 -62 -67
Operating Cash Flow to CapEx		 -5,003.98% -2,833.89% -3,306.64% -3,379.45% -10,773.30% -11,039.47% -4,536.99% -9,422.93% 338,604.76% -27,175.98% -7,773.53%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.05 0.05 0.02 0.02 0.00 0.01 0.01 0.01 0.18 0.20 0.21
Accounts Receivable Turnover		 4.63 204.24 64.20 148.58 1.17 666.67 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.65 3.69 2.28 1.71 0.54 0.93 0.89 0.88 26.19 25.46 25.74
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 78.89 1.79 5.69 2.46 312.76 0.55 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 78.89 1.79 5.69 2.46 312.76 0.55 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.10 -12 -6.10 -21 -20 -23 -27 -32 -45 -27 -36
Invested Capital Turnover		 -1.66 -1.33 -1.32 -0.81 -0.34 -0.41 -0.42 -0.26 -6.66 -8.79 -7.19
Increase / (Decrease) in Invested Capital		 22 12 11 -13 -17 -11 -21 -11 -25 -3.75 -8.61
Enterprise Value (EV)		 1,042 1,661 1,887 1,705 1,476 1,139 383 849 1,248 1,981 1,953
Market Capitalization		 1,553 2,293 2,828 2,657 2,676 2,221 1,434 1,841 2,385 3,031 2,926
Book Value per Share		 $8.83 $9.64 $12.45 $12.31 $13.97 $12.25 $11.70 $10.96 $12.46 $11.67 $10.67
Tangible Book Value per Share		 $8.83 $9.64 $12.45 $12.31 $13.97 $12.25 $11.70 $10.96 $12.46 $11.67 $10.67
Total Capital		 508 621 935 932 1,180 1,059 1,024 960 1,092 1,023 937
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -511 -633 -941 -953 -1,200 -1,082 -1,051 -992 -1,137 -1,050 -973
Capital Expenditures (CapEx)		 0.60 0.84 1.33 0.97 0.46 1.10 1.33 0.66 0.04 0.33 0.97
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -20 -14 -29 -28 -33 -35 -39 -49 -31 -40
Debt-free Net Working Capital (DFNWC)		 457 506 684 672 892 644 657 630 738 608 631
Net Working Capital (NWC)		 457 506 684 672 892 644 657 630 738 608 631
Net Nonoperating Expense (NNE)		 3.97 4.61 3.86 7.32 5.00 29 13 15 -11 17 23
Net Nonoperating Obligations (NNO)		 -511 -633 -941 -953 -1,200 -1,082 -1,051 -992 -1,137 -1,050 -973
Total Depreciation and Amortization (D&A)		 -2.54 -2.85 -5.23 -5.54 -4.35 -4.27 -2.65 -1.46 -0.95 -0.33 -0.07
Debt-free, Cash-free Net Working Capital to Revenue		 -48.81% -83.74% -92.74% -244.30% -725.82% -466.81% -506.89% -563.91% -22.69% -14.39% -17.72%
Debt-free Net Working Capital to Revenue		 1,947.24% 2,161.77% 4,414.01% 5,621.91% 22,726.36% 9,194.89% 9,386.09% 9,003.77% 343.59% 277.95% 280.23%
Net Working Capital to Revenue		 1,947.24% 2,161.77% 4,414.01% 5,621.91% 22,726.36% 9,194.89% 9,386.09% 9,003.77% 343.59% 277.95% 280.23%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.46) ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82) ($0.88) $1.35 ($0.93) ($1.11)
Adjusted Weighted Average Basic Shares Outstanding		 60.00M 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M 88.47M 88.53M 88.49M 88.70M
Adjusted Diluted Earnings per Share		 ($0.46) ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82) ($0.88) $1.33 ($0.91) ($1.11)
Adjusted Weighted Average Diluted Shares Outstanding		 60.00M 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M 88.47M 89.69M 88.49M 88.70M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 64.46M 74.56M 75.69M 84.48M 86.43M 87.54M 87.58M 87.64M 87.67M 87.81M 87.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -29 -36 -45 -47 -101 -59 -62 76 -66 -76
Normalized NOPAT Margin		 -291.97% -747.91% 0.00% 0.00% 0.00% -1,441.38% 0.00% 0.00% 36.53% -608.67% -1,158.24%
Pre Tax Income Margin		 -417.09% -1,135.71% 0.00% 0.00% 0.00% -2,222.61% 0.00% 0.00% 52.18% -562.39% -1,502.12%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

IDEAYA Biosciences (IDYA) has shown a highly volatile quarterly pattern over the last four years, with a standout profit in Q3 2025 followed by a significant quarterly loss in Q4 2025. Below are the 10 most important takeaways, focused on trends in revenue, profitability, cash flow, and balance sheet strength.

  • Q3 2025 profitability: Operating income of $108,452,000 and net income from continuing operations of $119,244,000, with diluted earnings per share of $1.33, marking a rare profitable quarter in the period.
  • Very strong gross margin in Q3 2025: Total revenue $207,834,000 and total cost of revenue $0, yielding gross profit of $207,834,000 (effectively 100% gross margin for that quarter).
  • Solid near-term cash generation in Q3 2025: Net cash from continuing operating activities of $142,214,000 and net change in cash & equivalents of $184,282,000, indicating meaningful cash generation that quarter.
  • Liquidity buffer outside the burn: As of Q3 2025, cash and short-term investments totaled roughly $0.8B (cash about $299M and short-term investments about $488M), supporting ongoing R&D and operations.
  • Revenue volatility remains a theme: A sharp quarterly spike in Q3 2025 (vs. Q4 2025) suggests revenue drivers may be episodic rather than a steady run-rate.
  • High and persistent R&D spend: R&D expense remains a major line item (e.g., $82.99M in Q3 2025 and $86.60M in Q4 2025), consistent with a biotech pipeline but depressing near-term margins.
  • Robust balance sheet capitalization: Total equity around $1.09B with relatively low liabilities (~$93M in Q3 2025), signaling strong capitalization versus assets.
  • Q4 2025 showed a material profit decline: Net income declined to -$83,273,000 and diluted EPS fell to -$0.91, indicating a sharp deterioration after the Q3 peak.
  • Prolonged operating cash burn in many prior quarters: Several quarters show negative net cash from operating activities (e.g., Q4 2024: -$121.7M; Q3 2024: -$49.2M; Q1–Q2 2025 also negative), highlighting ongoing cash burn before Q3 2025's spike.
  • Longer-term profitability risk persists: Across the four-year window, repeated net losses and negative EPS in most quarters point to substantial profitability risk until pipeline success translates into sustained revenue and margin improvements.
05/15/26 05:58 AM ETAI Generated. May Contain Errors.

IDEAYA Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, IDEAYA Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

IDEAYA Biosciences' net income appears to be on an upward trend, with a most recent value of -$113.70 million in 2025, rising from -$34.35 million in 2018. The previous period was -$274.48 million in 2024. View IDEAYA Biosciences' forecast to see where analysts expect IDEAYA Biosciences to go next.

IDEAYA Biosciences' total operating income in 2025 was -$159.31 million, based on the following breakdown:
  • Total Gross Profit: $218.71 million
  • Total Operating Expenses: $378.02 million

Over the last 7 years, IDEAYA Biosciences' total revenue changed from $0.00 in 2018 to $218.71 million in 2025, a change of 21,871,000,000.0%.

IDEAYA Biosciences' total liabilities were at $86.39 million at the end of 2025, a 33.0% increase from 2024, and a 1,117.1% increase since 2018.

In the past 7 years, IDEAYA Biosciences' cash and equivalents has ranged from $20.51 million in 2018 to $157.02 million in 2023, and is currently $112.83 million as of their latest financial filing in 2025.

Over the last 7 years, IDEAYA Biosciences' book value per share changed from -51.19 in 2018 to 11.67 in 2025, a change of -122.8%.


Related Companies

Financial statements for NASDAQ:IDYA last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel